PLEASANTON, CA--(Marketwire - October 04, 2007) - DALM 2007 -- Lipid Sciences, Inc. (NASDAQ: LIPD) -- In a presentation made today at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM 2007) in New York, Dr. H. Bryan Brewer, Jr., Chief Scientific Director of Lipid Sciences, Inc., announced the initial results of studies assessing the ability of Lipid Sciences' HDL mimetic peptide, LSI 518P, to mimic the principal functional characteristics of HDL. These studies showed that LSI 518P: 1)Significantly raised HDL in a mouse model following a single dose of the peptide; 2)Was highly effective in removing cholesterol from cholesterol-filled cells by the ABCA1 transporter; and 3)Decreased CD11B adhesion molecules -- thereby reducing the potential inflammation in the vessel wall associated with atherosclerosis.
